https://scholars.lib.ntu.edu.tw/handle/123456789/634326
標題: | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer | 作者: | Im, S-A Gennari, A Park, Y H Kim, J H Jiang, Z-F Gupta, S Fadjari, T H Tamura, K Mastura, M Y Abesamis-Tiambeng, M L T Lim, E H CHING-HUNG LIN Sookprasert, A Parinyanitikul, N Tseng, L-M Lee, S-C Caguioa, P Singh, M Naito, Y Hukom, R A Smruti, B K Wang, S-S Kim, S B Lee, K-H Ahn, H K Peters, S Kim, T W Yoshino, T Pentheroudakis, G Curigliano, G Harbeck, N |
關鍵字: | ESMO; Pan-Asian; guidelines; metastatic breast cancer; treatment | 公開日期: | 六月-2023 | 卷: | 8 | 期: | 3 | 來源出版物: | ESMO open | 摘要: | The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634326 | ISSN: | 20597029 | DOI: | 10.1016/j.esmoop.2023.101541 |
顯示於: | 醫學院附設癌醫中心醫院(臺大癌醫) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。